Balanced news tone
News Sentiment
DARE sentiment intelligence
Dare Bioscience Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
79/100 classification confidence.
directly relevant articles
high-authority source matches
-3.3% over one week, +0.0% over four weeks, trend active, and below fair value.
Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 Jul 2026 07:00
- Source
- StockStory
Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025
Daré Bioscience will host a conference call and live webcast on Monday, March 31, 2025, at 4:30 p.m. Eastern Time. The call will cover the company's financial results for the year ended December 31, 2024, and provide a general company update. Interested parties can access the cal
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 15:42
- Source
- 富途牛牛
[8-K] Dare Bioscience, Inc. Reports Material Event
Dare Bioscience, Inc. (DARE) has filed an 8-K report announcing the furnishing of a new corporate presentation dated July 13, 2026. This presentation is being used in meetings with securities market participants and will be available in the Investors section of the company's webs
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 15:42
- Source
- Stock Titan
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Dare Bioscience Company Profile & Introduction
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2026 03:06
- Source
- Moomoo
Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event
Sabrina Martucci Johnson, CEO of Daré Bioscience (NASDAQ: DARE), will participate in a Virtual Investor Closing Bell event on July 14, 2026, at 4:00 PM ET. She will provide a corporate overview, highlighting the recent launch of FloraSync LF5™, the company's commercial strategy,
- Tone
- Positive 75/100
- Event
- Market update
- Published
- 10 Jul 2026 02:10
- Source
- GlobeNewswire
Daré Bioscience CEO to discuss FloraSync launch, Q&A July 14
Daré Bioscience (NASDAQ: DARE) CEO Sabrina Martucci Johnson will participate in a Virtual Investor Closing Bell event on July 14, 2026, at 4:00 PM ET. She will provide a corporate overview, highlight the recent launch of FloraSync LF5™, discuss the company's growth strategy, and
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 12:14
- Source
- Stock Titan
Price to sales forward of Dare Bioscience, Inc. – NASDAQ:DARE
This article focuses on the "Price to sales forward" metric for Dare Bioscience, Inc. (NASDAQ: DARE). It appears to be a financial data page from TradingView, providing an overview of the company's financial performance. The content is primarily a navigation and site structure, w
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 04:10
- Source
- TradingView
DARE Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Dare Bioscience Inc (DARE). Based on various technical indicators and moving averages, the consensus for DARE is currently a "Sell." Key support is identified at $1.969 and resistance at $2.199, with the stoc
- Tone
- Negative 29/100
- Event
- Guidance
- Published
- 07 Jul 2026 12:41
- Source
- Intellectia AI
Daré Bioscience launches prescription-free vaginal probiotic capsule for microbiome support
Daré Bioscience has launched Flora Sync LF5, a prescription-free vaginal probiotic capsule containing Limosilactobacillus fermentum LF5, available through its direct-to-consumer platform. Clinical trials showed comparable efficacy to miconazole in treating vulvovaginal candidiasi
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 06 Jul 2026 18:11
- Source
- Contemporary OB/GYN
Price to earnings forward of Dare Bioscience, Inc. – NASDAQ:DARE
The article focuses on the "Price to earnings forward" metric for Dare Bioscience, Inc. (NASDAQ: DARE) as presented on TradingView. It appears to be a financial data page rather than a detailed analytical article, showing the company's financial overview within the health technol
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 05 Jul 2026 00:40
- Source
- TradingView
Enterprise value to EBIT forward of Dare Bioscience, Inc. – NASDAQ:DARE
The article focuses on the enterprise value to EBIT forward for Dare Bioscience, Inc., traded on the Nasdaq Stock Market under the ticker DARE. It appears to be a financial data point provided by TradingView, possibly within a larger financial analysis platform. The content prima
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jul 2026 20:39
- Source
- TradingView
Dare Bioscience (DARE) director receives 23,696 RSUs in lieu of cash pay
Dare Bioscience director Susan L. Kelley was granted 23,696 restricted stock units (RSUs) as compensation for her board service, replacing cash pay. Each RSU represents one share of common stock and will vest on January 4, 2027. Following this transaction, Kelley's direct holding
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 03 Jul 2026 00:10
- Source
- Stock Titan
Dare Bioscience (DARE) grants 38,862 RSUs to board director
Dare Bioscience (DARE) director William H. Rastetter has been granted 38,862 restricted stock units (RSUs) as compensation for his service on the board and its committees. These RSUs, granted at $0.00 per share, will vest on January 4, 2027, and directly increase his holdings to
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 20:40
- Source
- Stock Titan
Dare Bioscience (DARE) director receives 26,540 RSUs in lieu of cash fees
Dare Bioscience director Robin Joan Steele was granted 26,540 restricted stock units (RSUs) as compensation for her board service, replacing cash fees. These RSUs, which represent a contingent right to one common stock share each, will vest on January 4, 2027. Following this tran
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 02 Jul 2026 20:40
- Source
- Stock Titan
Dare Bioscience (DARE) director awarded 30,805 RSUs as board compensation
Dare Bioscience director Gregory W. Matz received 30,805 restricted stock units (RSUs) as compensation for his service on the company's board and committees. These RSUs convert into one share each upon vesting on January 4, 2027, and after this grant, Matz directly holds 30,847 s
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 20:40
- Source
- Stock Titan
Director Jessica Grossman gets 26,066 RSUs at Dare Bioscience (NASDAQ: DARE)
Jessica D. Grossman, a director at Dare Bioscience (NASDAQ: DARE), has been granted 26,066 Restricted Stock Units (RSUs) as non-cash compensation for her board service. These RSUs, valued at $0.00 per share for the grant, will fully vest on January 4, 2027, and each unit represen
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 20:40
- Source
- Stock Titan
Daré Bioscience’s vaginal probiotic is now for sale online
Daré Bioscience (NASDAQ: DARE) has launched Flora Sync LF5™, a non-hormonal vaginal probiotic capsule, directly to consumers through its DARE Health Hub, marking its first consumer product revenue stream. The product, priced at $49 per box, is formulated with a vagina-specific pr
- Tone
- Positive 67/100
- Event
- Earnings
- Published
- 01 Jul 2026 13:09
- Source
- Stock Titan
Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform
Daré Bioscience has launched Flora Sync LF5™, a vaginal probiotic capsule, making it available directly to consumers without a prescription. This launch signifies the company's transition into a revenue-generating entity, with Flora Sync LF5™ being its first consumer product. The
- Tone
- Positive 74/100
- Event
- Market update
- Published
- 01 Jul 2026 08:55
- Source
- GlobeNewswire
Dare Bioscience, Inc. Actuals & Estimates (NASDAQ:DARE)
This article provides an overview of Dare Bioscience, Inc. (NASDAQ:DARE) stock, covering current price, market capitalization, volatility, and historical performance. It also includes analyst forecasts for future prices, details on recent actual earnings and revenue compared to e
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 05:40
- Source
- TradingView
DARE Forecast — Price Target — Prediction for 2027
This article provides a forecast for Dare Bioscience, Inc. (DARE) stock, including analyst price targets, historical performance, and key financial metrics. It highlights that three analysts have a 1-year price forecast, with a current DARE price of $2.09, and discusses the compa
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 25 Jun 2026 20:40
- Source
- TradingView
Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 13:05
- Source
- GlobeNewswire
Daré Bioscience Highlights Revenue Opportunity as CEO
Daré Bioscience announced its participation in a Virtual Investor "What This Means" segment, where CEO Sabrina Martucci Johnson discussed the upcoming commercial launch of Flora Sync LF5™. This vaginal probiotic capsule marks the company's first consumer health product, positioni
- Tone
- Positive 75/100
- Event
- Earnings
- Published
- 25 Jun 2026 13:10
- Source
- GlobeNewswire
Daré Bioscience says Flora Sync LF5 could bring first product revenue
Daré Bioscience (NASDAQ: DARE) highlighted the upcoming June 2026 commercial launch of Flora Sync LF5™, a vagina-specific probiotic capsule intended to restore microbiome balance and support vaginal comfort. This product is Daré's first consumer health product and is anticipated
- Tone
- Positive 67/100
- Event
- Earnings
- Published
- 25 Jun 2026 13:10
- Source
- Stock Titan
Daré Bioscience, Inc. (DARE) Presents at BIO International Convention 2026 - Slideshow (NASDAQ:DARE) 2026-06-23
Daré Bioscience, Inc. (DARE) has published a slide deck in connection with its presentation at the BIO International Convention 2026. This article, provided by SA Transcripts, highlights the availability of these materials for investors.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 05:10
- Source
- Seeking Alpha
Form 8K Dare Bioscience Inc For: 22 June By Investing.com
This article announces the filing of a Form 8K by Dare Bioscience Inc. on June 22. It mentions DARE's current stock performance and is primarily a notice about the regulatory filing rather than an in-depth analysis.
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 22 Jun 2026 13:41
- Source
- Investing.com Canada
Dare Bioscience (DARE) unveils June 22, 2026 corporate investor presentation
Dare Bioscience (DARE) has released a new corporate investor presentation dated June 22, 2026, filed as Exhibit 99.1 under a Regulation FD disclosure. The presentation will be used for meetings with securities market participants and will be available on the company's website in
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 12:41
- Source
- Stock Titan
Dare Bioscience Inc (DARE) Institutional Confidence
The institutional confidence score for Dare Bioscience Inc (DARE) is 3.00, placing it 94th in the Pharmaceuticals industry. Institutional shareholding has increased by 23.58% quarter-over-quarter, now standing at 8.57% of outstanding shares. James Simons is the largest institutio
- Tone
- Positive 67/100
- Event
- Market update
- Published
- 18 Jun 2026 17:40
- Source
- TradingKey
Dare Bioscience Inc (DARE) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Dare Bioscience Inc (DARE), listing major individual and institutional holders and their percentage of ownership. It also provides a breakdown of shareholder types, including corporations, investment advisors, and hedge funds. Fur
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 15:11
- Source
- TradingKey
Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026
Daré Bioscience, a health biotech company focused on women's health, announced that its President and CEO, Sabrina Martucci Johnson, will participate in multiple speaking engagements and deliver a corporate presentation at the BIO International Convention 2026. The convention off
- Tone
- Positive 74/100
- Event
- Market update
- Published
- 18 Jun 2026 13:11
- Source
- GlobeNewswire